Cargando…

Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine

Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels we...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsunaga, Hidenori, Takeuchi, Hidefumi, Oba, Yuichiro, Fujimi, Satoshi, Honda, Tomoyuki, Tomonaga, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879303/
https://www.ncbi.nlm.nih.gov/pubmed/35214636
http://dx.doi.org/10.3390/vaccines10020177
_version_ 1784658866745638912
author Matsunaga, Hidenori
Takeuchi, Hidefumi
Oba, Yuichiro
Fujimi, Satoshi
Honda, Tomoyuki
Tomonaga, Keizo
author_facet Matsunaga, Hidenori
Takeuchi, Hidefumi
Oba, Yuichiro
Fujimi, Satoshi
Honda, Tomoyuki
Tomonaga, Keizo
author_sort Matsunaga, Hidenori
collection PubMed
description Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 °C; males: 37.1 °C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination.
format Online
Article
Text
id pubmed-8879303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88793032022-02-26 Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine Matsunaga, Hidenori Takeuchi, Hidefumi Oba, Yuichiro Fujimi, Satoshi Honda, Tomoyuki Tomonaga, Keizo Vaccines (Basel) Article Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 °C; males: 37.1 °C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination. MDPI 2022-01-24 /pmc/articles/PMC8879303/ /pubmed/35214636 http://dx.doi.org/10.3390/vaccines10020177 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matsunaga, Hidenori
Takeuchi, Hidefumi
Oba, Yuichiro
Fujimi, Satoshi
Honda, Tomoyuki
Tomonaga, Keizo
Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title_full Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title_fullStr Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title_full_unstemmed Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title_short Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
title_sort waning of anti-sars-cov-2 spike antibody levels 100 to 200 days after the second dose of the bnt162b2 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879303/
https://www.ncbi.nlm.nih.gov/pubmed/35214636
http://dx.doi.org/10.3390/vaccines10020177
work_keys_str_mv AT matsunagahidenori waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine
AT takeuchihidefumi waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine
AT obayuichiro waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine
AT fujimisatoshi waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine
AT hondatomoyuki waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine
AT tomonagakeizo waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine